Malaria causes significant morbidity in Malawi, with an estimated 5 million cases in 2014. Artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) are the first- and second-line treatments for uncomplicated malaria, respectively, but emerging resistance threatens their efficacy. In order to understand whether AL and ASAQ remain efficacious for the treatment of uncomplicated Plasmodium falciparum malaria in Malawi, a therapeutic efficacy trial was conducted.
Peter Troell合作论文数1
Daniel Marthey合作论文数College Pk, Univ Maryland1Don Mathanga合作论文数Malaria Alert Center, College of Medicine, University of Malawi1Sande John合作论文数1Luka Madalitso合作论文数1
Dyson Mwandama合作论文数1Paczkowski Magdalena M合作论文数1
Julie Gutman合作论文数Hubert Department of Global Health, Rollins School of Public Health, Emory University;Malaria Branch, Centers for Disease Control and Prevention1Doreen Ali合作论文数1
